Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisGupta V, Gotlib J, Radich J, Kröger N, Rondelli D, Verstovsek S, Deeg HBIOL BLOOD MARROW TR. 2016;95(6):967-72. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.Shimoni A, Kröger N, Zabelina T, Ayuketang Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander A, Nagler ALEUKEMIA. 2013;19(12):1661-9. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.van de Donk N, Kröger N, Hegenbart U, Corradini P, San Miguel J, Goldschmidt H, Perez-Simon J, Zijlmans M, Raymakers R, Montefusco V, Ayuketang Ayuk F, van Oers M, Nagler A, Verdonck L, Lokhorst HBONE MARROW TRANSPL. Transplant results in adults with Fanconi anaemiaBierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta P, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak G, Othman T, Halkes C, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano A, Ehninger G, Porcher R, Dufour CBRIT J HAEMATOL. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapyBerdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse BHUM VACC IMMUNOTHER . Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosisRobin M, de Wreede L, Wolschke C, Schetelig J, Eikema D, Van Lint M, Knelange N, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger NHAEMATOLOGICA. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantationNagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, Itäla-Remes M, Yakoub-Agha I, Labussière-Wallet H, Gallego-Hernanz M, Deconinck E, Chevallier P, Finke J, Esteve J, Mohty MAM J HEMATOL. 2020;95(7):809-816. ELN-SIE evidence-based recommendationsMarchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian J, Kröger N, McMullin M, Passamonti F, Vannucchi A, Barbui TLEUKEMIA. Uni-Med, 56-63. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty MBONE MARROW TRANSPL. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.Zander A, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel W, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat WANN ONCOL. Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell TransplantationEssmann S, Heestermans M, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake CTRANSPL CELL THER. 2022;57(5):817-823. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteriaAyuketang F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger NANN HEMATOL. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.Lehnert M, Mross K, Schueller J, Thuerlimann B, Kröger N, Kupper HBRIT J CANCER. 2013;19(11):1534-6. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid LeukemiaSchetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede L, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee S, Kröger N, Hsu K, Schmidt A, Yakoub-Agha I, Robin MFRONT IMMUNOL. 2016;51(9):1223-7. 2017;23(12):2184-2191. Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMichallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox C, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig JBONE MARROW TRANSPL. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell TransplantationZeiser R, Beelen D, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann J, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LBIOL BLOOD MARROW TR. Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCTEsser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Schilling G, Götze H, Scherwath ABONE MARROW TRANSPL. 2015;86(8):989-96. Switzerland: Springer Open, 569 - 578. Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübig T, Sierich H, Badbaran A, Eiermann T, Binder T, Kröger NClin Dev Immunol. A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myelomaSchieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder MBLOOD. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.Kröger NHEMATOL-AM SOC HEMAT. 2010;116(15):3621-3630. Second allogeneic stem cell transplantation in myeloid malignancies.Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuketang Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander A, Bacher UACTA HAEMATOL-BASEL. Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaNagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt H, Finke J, Franke G, Ciceri F, Verbeek M, Blau I, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani B, Mohty MBONE MARROW TRANSPL. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. Institut für Humangenetik, UKE Praxis für Humangenetik, Prof. Dr. med. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemiaKharfan-Dabaja M, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty MBRIT J HAEMATOL. Acute hepatitis as a prequel to very severe aplastic anemiaWeiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit MZ GASTROENTEROL. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effectsJansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, Salwender H, Einsele H, Kröger N, Beelen D, Dreger P, Goldschmidt H, Brenner HLEUKEMIA LYMPHOMA. IMWG consensus on risk stratification in multiple myelomaChng W, Dispenzieri A, Chim C, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J, Sonneveld P, Cavo M, Usmani S, Durie B, Avet-Loiseau HLEUKEMIA. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.Kröger N, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander ABLOOD. 2019;104(4):659-668. 2014;50(2):209-215. Cham: Springer International Publishing, 203-206. 2017;177(5):759-765. Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromeAyuk F, Beelen D, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner E, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn P, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge WBIOL BLOOD MARROW TR. 2012;32(5):2031-2034. 2010;51(1):146-148. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander A, Baccarani M, Bacher UACTA HAEMATOL-BASEL. 2021;106(5):606-615. 2010;148(2):323-331. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT studyRuggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, Michallet M, Stelljes M, Jindra P, Arnold R, Kröger N, Mohty M, Nagler AJ HEMATOL ONCOL. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemiaCraddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis J, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty MHAEMATOLOGICA. Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1 yearSamek M, Iversen K, Belmar Campos C, Berneking L, Langebrake C, Wolschke C, Ayuk F, Kröger N, Christopeit MEUR J HAEMATOL. 2014;49(2):168-73. Weiterlesen ASCO Annual Meeting Aktuelle Neuigkeiten aus der Onkologie direkt vom Kongress Das ASCO Annual Meeting in Chicago ist der weltweit größte und wichtigste Kongress der klinischen Onkologie. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.Schetelig J, Kröger N, Held T, Christian T, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander A, Siegert WHAEMATOLOGICA. Unklare Panzytopenie bei einem 52-jährigen PatientenHeidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke CINTERNIST. 2019;54(8):1179-1188. 2021;96(1):40-50. 2008;41(10):913-916. 2017;31(11):2523-2525. 2022;57(1):144. 2020;34(1):317-321. 2016;17(9):E1515. 2020;189(5):e213-e217. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosisAlchalby H, Yunus D, Zabelina T, Ayuketang F, Kröger NBONE MARROW TRANSPL. 1990;335(8696):1031-2. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. 2022;107(5):1054-1063. 2011;25(1):75-81. 2021;34(4):. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMTMachowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema D, de Wreede L, Blok H, Isaksson C, Einsele H, Poiré X, van Dorp S, Nikolousis E, Johansson J, Kobbe G, Zecca M, Arnold R, Gerbitz A, Finke J, Díez-Martín J, Bonifazi F, McQuaker G, Lenhoff S, Rohrlich P, Theobald M, Ljungman P, Collin M, Albert M, Ehninger G, Carlson K, Halaburda K, Lehmberg K, Schönland S, Yakoub-Agha I, Gennery A, Lankester A, Kröger NBONE MARROW TRANSPL. 2017;31(10):2161-2171. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantationSchroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe GLEUKEMIA. 2006;91(6):750-756. 1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantationPeter K, Siska P, Roider T, Matos C, Bruns H, Renner K, Singer K, Weber D, Güllstorf M, Kröger N, Wolff D, Herr W, Ayuk F, Holler E, Stark K, Heid I, Kreutz MBONE MARROW TRANSPL. 2015;21(7):1230-1236. 2013;48(11):1395-400. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow TransplantationAlchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn J, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger NBIOL BLOOD MARROW TR. 2006;34(5):688-694. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantationBattipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg J, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty MBLOOD. Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple MyelomaLajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Kröger N, Atanackovic DBRIT J HAEMATOL. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasmsParampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf DBRIT J HAEMATOL. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factorsStyczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden J, Kröger N, Mohty M, Gratwohl ABONE MARROW TRANSPL. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationCarré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon M, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub Agha I, Kröger N, Robin MBIOL BLOOD MARROW TR. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander A, Fehse B, Bokemeyer C, Kröger NHAEMATOLOGICA. 2023;108(2):655-656. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTChalandon Y, Passweg J, Guglielmi C, Iacobelli S, Apperley J, Schaap N, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria EHAEMATOLOGICA. Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)Mohseny A, Eikema D, Neven B, Kröger N, Shaw P, Damaj G, Dalle J, Bosman P, Delehaye F, Lankester A, Smiers F, Peffault de Latour RJ PEDIAT HEMATOL ONC. Transplantation in CML in the TKI era: who, when, and how?Niederwieser C, Kröger NHEMATOL-AM SOC HEMAT. 2019;12(1):108. 2013;122(11):1848-50. Efficacy and outcome of allogeneic transplantation in IgD and non secretory myeloma. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in GermanyBethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus C, Vucinic V, Mougiakakos D, Topp M, Fante M, Schroers R, Bayir L, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen D, Lengerke C, Kroeger N, Dreger PBLOOD. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuketang Ayuk F, Dahlke J, Eiermann T, Zander ATRANSPLANTATION. Which patients with myelofibrosis should receive ruxolitinib therapy? Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels B, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic DClin Dev Immunol. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004.Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen D, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb H, Kröger N, Zander AANN HEMATOL. 2021;21(10):686-693. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019McLornan D, Yakoub-Agha I, Robin M, Chalandon Y, Harrison C, Kroger NHAEMATOLOGICA. 2008;42(2):121-128. 2006;108(9):2928-2936. Comparison of flow cytometry vs. a haematology cell analyser-based method to guide the optimal time-point for peripheral blood stem cell apheresis.Gutensohn K, Magens M, Krüger W, Kröger N, Kühnl PVOX SANG. Dirk Arnold Innere Medizin, Hämatologie und Internistische Onkologie, Palliativmedizin Paul-Ehrlich-Str. 2018;103(3):514-521. 2013;27(10):2072-5. 2017;52(2):191-196. 2013;161(1):87-94. 2019;134(21):1832-1846. Current Challenges in Stem Cell Transplantation in MyelofibrosisKröger NCURR HEMATOL MALIG R. 2015;10(4):344-50. Outcome of allo-SCT for chronic myelomonocytic leukemia.Ocheni S, Kröger N, Zabelina T, Zander A, Bacher UBONE MARROW TRANSPL. 2022;28(19):4258-4266. 2022;28(2):115.e1-115.e5. 2020;104(4):318-327. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant settingAtanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki J, Bokemeyer CHUM VACC IMMUNOTHER . Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl M, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel W, Ehninger G, Beelen D, Schetelig J, Stelljes MLANCET ONCOL. 2010;51(8):1530-1535. 2011;126(4):234-237. Major central nervous system complications after allogeneic stem cell transplantation: a large retrospective study on 888 consecutive adult patientsMannina D, Berneking L, Both A, Timm W, Urbanowicz T, Wolschke C, Ayuk F, Fischer N, Fiehler J, Grzyska U, Rösner S, Choe C, Kröger N, Christopeit MEUR J HAEMATOL. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMTvan Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen N, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig JCL LYMPH MYELOM LEUK. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined SignificancePiechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid CDTSCH ARZTEBL INT. Zentrum für Onkologie; II. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx AEXP MOL PATHOL. 2020;136(12):1442-1455. 2008;60-67. Clinical features of hepatitis E infections in patients with hematologic disordersGhandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann FHAEMATOLOGICA. Aufl. 2019;25(3):522-528. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMTForcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, Koster L, Ganser A, Volin L, Sengeloev H, Michallet M, Tischer J, Jindra P, Cascon M, Koc Y, Arat M, Tomaszewska A, Hayden P, de Witte T, Yakoub-Agha I, Kröger N, Robin MBONE MARROW TRANSPL. 2014;49(6):744-50. 2013;41(2):133-134. 2021;56(8):1944-1952. 2007;92(2):275-276. 2022;28(7):374.e1-374.e9. 2021;12:. 2020;55(6):1093-1102. 2018;24(10):2152-2156. Chancen und Risiken der CAR-T-Zell-TherapieAyuk F, Fehse B, Berger S, Riecken K, Kroger NHamb Ärztebl. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey reportPassweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden J, Styczynski J, Mohty MBONE MARROW TRANSPL. 2021;56(10):2367-2381. Die Klinik für Augenheilkunde des Universitätsklinikums Hamburg-Eppendorf (UKE) bietet eine Sprechstunde für seltene Augenerkrankungen an: Dort werden Patient:innen mit erblichen und komplexen Netzhauterkrankungen behandelt. 2014;370(19):1781-9. 2022;60(5):. 2019;60(10):2404-2414. 2020;38(29):3357-3360. 2021;106(8):2054-2065. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde FBLOOD. 2019;73(10):30-32. 2020;55(1):126-136. 2019;104(11):2274-2282. Autologous haematopoietic cell transplantation in elderly patients with multiple myelomaAuner H, Garderet L, Kröger NBRIT J HAEMATOL. 2012;104(13):1005-1020. 2000;78(2):101-105. Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideMorris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff G, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kröger N, de Witte T, Ruutu TTRANSFUSION. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.Carreras E, Cahn J, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant JANTICANCER RES. 2019;54(4):497-507. 2021;56(11):2834-2841. Biology of relapse after transplantationGress R, Miller J, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Landau D, Wu CBIOL BLOOD MARROW TR. 2020;10(6):2645-2658. 2004;10(10):698-708. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomeraseLanger F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf WBLOOD. 2010;45(1):13-9. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyLjungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani M, Apperley J, Berceanu A, Bofarull R, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox M, Grassi A, Jimenez M, Demir S, Kwon M, Llamas C, Lorenzo J, Mielke S, Orchard K, Porras R, Vallisa D, Xhaard A, Knelange N, Cedillo A, Kröger N, Piñana J, Styczynski JLEUKEMIA. Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic LeukemiaBazarbachi A, Labopin M, Kröger N, Brecht A, Blaise D, Clausen J, Fanin R, Einsele H, Cavanna L, Itäla-Remes M, Bulabois C, Kündgen L, Martin H, Schmid C, Wagner-Drouet E, Alakel N, Bazarbachi A, Savani B, Nagler A, Mohty MCL LYMPH MYELOM LEUK.
Pössl Wohnmobile Kaufen, Articles O